Key Insights

Highlights

Success Rate

92% trial completion (above average)

Published Results

98 trials with published results (11%)

Research Maturity

572 completed trials (64% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.8%

52 terminated out of 895 trials

Success Rate

91.7%

+5.2% vs benchmark

Late-Stage Pipeline

19%

170 trials in Phase 3/4

Results Transparency

17%

98 of 572 completed with results

Key Signals

98 with results92% success52 terminated

Data Visualizations

Phase Distribution

518Total
Not Applicable (215)
Early P 1 (9)
P 1 (51)
P 2 (73)
P 3 (59)
P 4 (111)

Trial Status

Completed572
Unknown144
Recruiting61
Terminated52
Active Not Recruiting24
Withdrawn21

Trial Success Rate

91.7%

Benchmark: 86.5%

Based on 572 completed trials

Clinical Trials (895)

Showing 20 of 20 trials
NCT01143454Recruiting

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143480Recruiting

Study of the Effect of Innate on the Inflammatory Response to Endotoxin

NCT00353782Recruiting

Causes and Natural History of Dyslipidemias

NCT05994014Not ApplicableRecruiting

PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]

NCT07448038Phase 2RecruitingPrimary

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

NCT05867381Not ApplicableRecruiting

Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History

NCT01399385Not ApplicableRecruiting

New Heart Imaging Techniques to Evaluate Possible Heart Disease

NCT04167761Early Phase 1Completed

Ertugliflozin: Cardioprotective Effects on Epicardial Fat

NCT07625488Enrolling By Invitation

Measuring Athlete's Risk of Cardiovascular Events 3 (MARC-3)

NCT04496947Not ApplicableRecruitingPrimary

Pilot Study Evaluating the Impact of Stress Reduction on Atherosclerotic : Heart and Mind Study

NCT02505399Phase 4CompletedPrimary

TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement

NCT07614230Phase 4Recruiting

SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes

NCT07613294Phase 3Not Yet RecruitingPrimary

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

NCT07611747Phase 4Recruiting

Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)

NCT07524101Not ApplicableNot Yet Recruiting

Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD

NCT05470218Not ApplicableActive Not RecruitingPrimary

Leucine, mTOR and Athero

NCT05235464Not ApplicableRecruitingPrimary

High Protein Diet and Atherosclerosis

NCT00725868Not ApplicableCompletedPrimary

Blood Endothelium Biomarkers to Predict Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention

NCT06402747Phase 4Recruiting

Clopidogrel Versus Cilostazol on Vessels

NCT05365425Phase 4Recruiting

Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

Scroll to load more

Research Network

Activity Timeline